GuidelineClinical pharmacology and therapeutics2017
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
Registry-linked trialAbstract readPractice Guideline
In one paragraph
Guideline in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05091879 (Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population), which is not on this map. Cited by 351 papers, 11 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
351citing papers in PubMed, 11 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population
Who cites it
351 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Economic effectiveness of pharmacogenomics-guided prescribing for psychiatric disorders: a systematic review and meta-analysis.The pharmacogenomics journal · 2026Pooled it
- Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and CYP2C19 and tricyclic antidepressants.European journal of human genetics : EJHG · 2026Guideline
- Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine.Annals of laboratory medicine · 2025Guideline
- Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms.Journal of child and adolescent psychopharmacology · 2025Pooled it
- Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis.Journal of psychopharmacology (Oxford, England) · 2024Pooled it
- Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.Translational psychiatry · 2024Pooled it
- Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT.BMC psychiatry · 2023Pooled it
- Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.International journal of molecular sciences · 2023Pooled it
- Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials.Clinical pharmacology and therapeutics · 2022Pooled it
- Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy.BMC psychiatry · 2022Pooled it
- Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Pooled it
- Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing.Clinical pharmacokinetics · 2025Trial
- Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.Drug metabolism and disposition: the biological fate of chemicals · 2024Trial
- CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial.Pharmacotherapy · 2023Trial
- Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Association of Native American, European, and African Ancestry with CYP450 Pharmacogenetics and Metabolic Phenotypes in Admixed Latin American Populations from Ecuador and Nicaragua.Pharmaceuticals (Basel, Switzerland) · 2026Article
- preSCRIPT: Large-scale prescription search and annotation engine for pharmacogenomic studies.Pharmacological reports : PR · 2026Article
- Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response.The pharmacogenomics journal · 2026Article
- BioFRAM PGx, an Implementation Proposal for Pharmacogenetics in the Spanish National Health System.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A de novo algorithm for allele reconstruction from Oxford nanopore amplicon reads, with application to CYP2D6.Bioinformatics (Oxford, England) · 2026Article
291 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
J K HicksDeBartolo Family Personalized Medicine Institute, Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
K SangkuhlDepartment of Genetics, Stanford University, Stanford, California, USA.
J J SwenDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
V L EllingrodDepartment of Clinical, Social and Administrative Sciences, College of Pharmacy, and Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
D J MüllerCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
K ShimodaDepartment of Psychiatry, Dokkyo Medical University, Japan.
J R BishopDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, and Department of Psychiatry, College of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
E D KharaschDivision of Clinical and Translational Research, Department of Anesthesiology, Washington University in St, Louis, St, Louis, Missouri, USA.
T C SkaarDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
A GaedigkDivision of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy, Kansas City, Missouri and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA.
H M DunnenbergerCenter for Molecular Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA.
T E KleinDepartment of Genetics, Stanford University, Stanford, California, USA.
K E CaudleDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
J C StinglDivision of Research, Federal Institute of Drugs and Medical Devices, Bonn, Germany.
Funding
PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2MIndiana PROSPECTR01HS019818 · AHRQ · INDIANA UNIVERSITY INDIANAPOLIS · PI DEXTER, PAUL · 2010 to 2010
$8.4MMETHADONE AND HIV DRUG INTERACTIONSR01DA014211 · NIDA · WASHINGTON UNIVERSITY · PI KHARASCH, EVAN D. · 2001 to 2012
$4.8MFolate Pharmacogenomics and Risk of Atypical Antipsychtoic Metabolic Side EffectsR01MH082784 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELLINGROD, VICKI L · 2008 to 2017
$4.0MRegulation of drug metabolizing enzymes by miRNAsR01GM088076 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI SKAAR, TODD C. · 2009 to 2017
$3.8MClinical Pharmacogenetics Implementation Consortium (CPIC)R24GM115264 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KLEIN, TERI ELLEN, RELLING, MARY V · 2015 to 2017
$3.6MNovel noninvasive assessment of cytochrome P450 activityR01GM063674 · NIGMS · WASHINGTON UNIVERSITY · PI KHARASCH, EVAN D. · 2001 to 2009
$1.8MAHRQ HHS R01 HS019818CIHRNIDA NIH HHS R01 DA014211NIGMS NIH HHS R01 GM063674NIGMS NIH HHS R01 GM088076NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM115264NIMH NIH HHS R01 MH082784
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antidepressive Agents, TricyclicCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Dose-Response Relationship, DrugGenotyping TechniquesHumansMedication Therapy ManagementPharmacogenomic VariantsPolymorphism, GeneticTreatment OutcomeAntidepressive Agents, TricyclicCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05091879ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.